For all the success that drug-eluting stents (DES) have had in preventing restenosis, there is increasing data showing that in a small number of patients, these implants also can produce significant adverse events resulting from late-stage thrombosis. To address that problem, Medtronic Inc. has gained rights to ReVas, a drug development program based on novel targets of vascular inflammation, from Resverlogix Inc.
Donald J. McCaffrey, president and CEO of Calgary, Alberta-based Resverlogix, points out that the two DES currently approved for US use—the Cypher from Cordis Corp. and the Taxus from...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?